Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
2.
CMAJ ; 158(2): 231-4, 1998 Jan 27.
Article in English | MEDLINE | ID: mdl-9469147

ABSTRACT

IN WINNING FIRST PRIZE in the Logie Medical Ethics Essay Contest in 1997, Dr. Fady Moustarah made a strong and compelling argument in favour of presumed consent in the procurement of donor organs. He stressed that a major education campaign will be needed when such a policy is adopted lest some people begin to regard physicians as "organ vultures."


Subject(s)
Attitude to Health , Ethics, Medical , Health Education/organization & administration , Health Policy/legislation & jurisprudence , Informed Consent/legislation & jurisprudence , Tissue and Organ Procurement/organization & administration , Canada , Health Care Rationing , Humans , Personal Autonomy , Resource Allocation , Risk Assessment , Waiting Lists
3.
J Rheumatol ; 22(11): 2027-33, 1995 Nov.
Article in English | MEDLINE | ID: mdl-8596139

ABSTRACT

OBJECTIVE: To determine the relationship of DR1, DR4, and DR4 subtypes with disease severity in patients with rheumatoid arthritis (RA). METHODS: We studied a cohort of 103 Caucasian patients with an onset of disease in 1985, and 6 to 7 years of disease at the time of the study. All rheumatologists in Edmonton participated in the city wide study which included hospital and community based patients with mild and severe disease. HLA status was determined using polymerase chain reaction amplification and amplified fragment length polymorphism typing. Outcome measures included joint counts, radiological scores, and physical functional status. RESULTS: Fifty-six patients (54%) were DR4 positive, (OR = 2.3, 95% CI 1.4-3.6, compared to controls). This association was only statistically significant for seropositive patients (OR = 2.8 in seropositive patients and OR = 1.5 in seronegative patients). A higher risk was observed for DR1/DR4 heterozygotes (OR = 6.8 in seropositive patients and OR = 1.7 in seronegative patients). No significant differences were observed in disease activity, joint counts, radiological scores, or functional status among patients carrying 1, 2 or no disease related alleles, although the prevalence of rheumatoid factor (RF) showed a linear association with allele dose (0, 1, or 2). CONCLUSION: DR4 and in particular DR1/DR4 heterozygosity were related to susceptibility to RA only in seropositive patients. RF was a better predictor of severity than disease related HLA subtypes. These findings suggest that the effect of these alleles on severity may be related to seropositivity, or that perhaps, seropositive and seronegative RA are genetically distinct entities. The results of our study suggest that in community based settings, which include patients with milder disease, DR1 and DR4 disease related alleles increase susceptibility for RA, but are not clinically useful as predictors of longer term outcome.


Subject(s)
Arthritis, Rheumatoid/immunology , HLA-DR Antigens/analysis , HLA-DR1 Antigen/analysis , HLA-DR4 Antigen/analysis , Alleles , Arthritis, Rheumatoid/genetics , Arthritis, Rheumatoid/physiopathology , Cohort Studies , Disease Progression , Disease Susceptibility , Genotype , HLA-DR1 Antigen/genetics , HLA-DR4 Antigen/genetics , HLA-DRB1 Chains , Heterozygote , Humans , Middle Aged , Reference Values , Regression Analysis , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL